Correction of Complications of Endometriosis by Curcumin Nanomicelle Supplement in Treated Wome
Not Applicable
Recruiting
- Conditions
- Endometriosis.Endometriosis of OvaryN80.1
- Registration Number
- IRCT20170923036334N4
- Lead Sponsor
- Iranian academic center for education culture and research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Age between 20-40 Years
Endometriosis With Grade 2 and 3
Exclusion Criteria
No ovulation
Male factor infertility
Pelvic organ prolapse
Congenital adrenal hyperplasia
Thyroid hormone disorders
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of serum levels of sex hormone. Timepoint: Before taking the drug and 10 weeks after taking the drug. Method of measurement: Eliza Kit.;Evaluation of biochemical factors. Timepoint: Before taking the drug and 10 weeks after taking the drug. Method of measurement: Abnova commercial kits using ELISA method.;Measurement of Plasma Curcumin Levels. Timepoint: Before Taking the Drug and 10 Weeks After Taking the Drug. Method of measurement: Negative Electrospray Ionization (ESI) and Data are Analyzed Using MassLynx v4.0 Software.;Apoptosis Levels. Timepoint: Before Taking the Drug and 10 weeks After Taking the Drug. Method of measurement: Tunnel Kit.
- Secondary Outcome Measures
Name Time Method Fertility Rate. Timepoint: One Day After Injection of Sperm into the Cytoplasm of the Oocyte. Method of measurement: Fertilization is Seen with an Inverted Microscope.;Embryo Quality. Timepoint: Three Days After Sperm is Injected into the Cytoplasm of the Oocyte. Method of measurement: Embryo Quality is Assessed Based on the Number of Cells and the Number of Blastomeres and the Fragmentation of the Blastomeres and is Observed Under an Inverted Microscope.